ALT vs CRL · rev $5.0K vs rev $2.00B
Altimmune Inc (ALT) versus Charles River Laboratories (CRL) — a side-by-side from cached financials, not a winner call.
Altimmune Inc (ALT) is a biotechnology company listed on US.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Latest reported ALT revenue for 2025-09-30 was $5.0K. Net income was -$60.7M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. ALT currently screens at market cap $527.0M.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
ALT currently screens at market cap $527.0M. CRL currently screens at market cap $7.78B.
Not investment advice. Open the ALT and CRL stock pages for the full models.
Not investment advice.